BridgeBio Pharma, Inc.

NASDAQ:BBIO

Biotechnology

Healthcare
$78.01 +1.13%

+$0.75 today

Market cap
$15.20B
Beta
0.97
P/E (TTM)
-18.1
EPS (TTM)
-$3.73
52W Low $40.19High $84.94

Volume 3.55M

Average 2.49M

BBIO Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

BridgeBio Pharma, Inc.NASDAQ: BBIO

Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026

Selling, general & admin grows, but more slowly than its trailing trend

Q2 FY2026 selling, general & admin of $186.26M rose 44.2% year over year, behind the +67.8% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 13.6% from the prior quarter. Over 3 fiscal years it compounded at +57.1% a year.

Context

  • Selling, general & admin amounted to 110.6% of revenue in FY2025, down 19.6 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 13 analysts of $5.05B (+810.4%) for the fiscal year ending Dec 2026, a step up from the +92.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$186.26M+13.6% QoQ
Last fiscal yearDec 2025
$555.14M+92.1% YoY
LTMJun 2026
$669.78M+67.8% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+44.2%+889.3%+845.1 pp
1 year+92.1%+810.4%+718.3 pp
3-year CAGR+57.1%+178.4%+121.3 pp
5-year CAGR+108.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
555.14M USD
Year-over-year change
+92.1%
4-year CAGR
+30.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How BBIO compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +67.8% is the 2nd highest of 11, against a peer median of +27.8%.
  • Selling, general & admin amounts to 93.9% of revenue for BBIO, versus a peer median of 55.1%.
BBIO Competitors
Selling, General & Admin for BBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$335.1B USD+34325.1%+15.8%32.6%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$1.32B USD+22.1%+16.3%27.4%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026$669.78M USD+67.8%+57.1%93.9%
ASNDAscendis Pharma A/SLTM Sep 2026€598.18M EUR+52.7%+26.4%49.5%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$584.98M USD+66.3%+37.9%61.0%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$376.47M USD+23.4%+19.5%57.8%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$351.33M USD+8.3%+2.1%34.8%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$350.27M USD+5.7%+7.9%52.3%
SRRKScholar Rock Holding CorporationLTM Sep 2026$198.39M USD+32.1%+60.5%34804.4%
DNLIDenali Therapeutics Inc.LTM Jun 2026$139.03M USD+19.2%+2.4%3857.6%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$39.04M USD+38.9%+14.7%195.2%
Peer median (excluding BBIO) —+27.8%+16.0%55.1%

Competitors are the stored peer set for BBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue69.72M77.65M9.3M221.9M502.08M
Cost of Revenue3.11M3.43M2.45M3.88M28.27M
Gross Profit66.6M74.21M6.86M218.02M473.81M
Gross Margin95.5%95.6%73.7%98.3%94.4%
Research & Development451.02M399.46M455.71M506.46M477.54M
Selling, General & Admin192.21M143.19M150.59M288.93M555.14M
Operating Expenses643.23M586.42M614.23M811M1.04B
Depreciation & Amortization5.84M6.77M6.49M6.08M5.43M
EBITDA(533.83M)(397.44M)(565.47M)(436.83M)(676.45M)
EBITDA Margin-765.7%-511.9%-6078.3%-196.9%-134.7%
Operating Income(576.63M)(512.2M)(607.37M)(592.97M)(569.09M)
Operating Margin-827.1%-659.6%-6528.8%-267.2%-113.3%
Interest Income1.13M7.54M18.04M17.25M19.85M
Interest Expense46.78M80.44M81.29M99.29M53.1M
Other Income / Expenses(9.82M)27.55M(45.88M)50.78M(165.9M)
Income Before Tax(586.45M)(484.65M)(653.25M)(542.19M)(734.99M)
Pre-Tax Margin-841.2%-624.2%-7021.9%-244.3%-146.4%
Income Tax Expense0001.15M555K
Net Income(562.54M)(481.18M)(643.2M)(535.76M)(729.31M)
Net Margin-806.9%-619.7%-6913.9%-241.4%-145.3%
EPS (Basic)(3.90)(3.35)(3.95)(2.88)(3.79)
EPS (Diluted)(3.90)(3.35)(3.95)(2.88)(3.79)
Weighted Avg Shares144.36M147.47M162.79M186.08M197.24M
Weighted Avg Shares (Diluted)144.36M147.47M162.79M186.08M197.24M

BridgeBio Pharma, Inc.

NASDAQ:BBIO

Intrinsic Alpha fair value

Locked

Current Price

$78.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.